7fd400d1bdcf1839fee87498bceec5d5 327777.pdf 57473f45f17ebd901efedb48218248a07a7527e1 327777.pdf e81e67918b759ccee82096da6e6ff77aaf3c4b33b6f361378165cc50893928d1 327777.pdf Title: Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab Subject: Background: This study aimed to evaluate the clinical effectiveness of dupilumab and its impact on CRSwNP and type 2 inflammatory biomarkers in patients with severe uncontrolled asthma, with or without comorbidities, within a real-life cohort. Methods: This was a single-center, prospective, and observational real-life study conducted at the Severe Asthma Unit of Germans Trias i Pujol University Hospital. The objective of this study was to assess the real-world response to dupilumab treatment in patients with severe asthma, with or without nasal polyposis, bronchiectasis, obesity, or switching from another biologic drug for their asthma. Results: The ACT score significantly increased (13.7 vs. 20.6; p = 0.001), while the number of exacerbations decreased (3.1 vs. 0.7; p = 0.005). Patients with CRSwNP showed an increase in the ACT score (13.1 vs. 19.8; p = 0.011) and a decrease in the number of exacerbations (3.0 vs. 1.3; p = 0.217). Patients with nasal polyps showed an increase in both SNOT22 (78.3 vs. 38.3; p = 0.013) and global VAS (8 vs. 4.2; p = 0.028). Patients with bronchiectasis receiving dupilumab showed an increase in the ACT score (12.7 vs. 21.3; p = 0.039) and a marked decrease in the number of exacerbations (2.8 vs. 0; p = 0.025). Obese patients treated with dupilumab showed an improvement in the ACT score (14.1 vs. 21.3; p = 0.044) and a decrease in the rate of exacerbations (3.2 vs. 1.3; p = 0.030). Patients with rhinoconjunctivitis receiving dupilumab showed an increase in the ACT score (13.4 vs. 19.1; p = 0.017) and a decrease in the number of exacerbations (3.3 vs. 0.8; p = 0.024). Conclusions: Dupilumab is a highly effective treatment for severe asthma, showing significant improvements in lung function, reductions in exacerbations, and enhanced quality of life for patients with and without nasal polyps. The results of this real-life study support dupilumab as a valuable addition to the therapeutic armamentarium for asthma, particularly for those with type 2 inflammation despite the presence of comorbidities such as bronchiectasis or obesity, or for patients in whom a previous biologic treatment failed. Keywords: asthma; comorbidities; dupilumab; personalized medicine; real-life study Author: Carlota Gonzalez-Lluch, Maria Basagaña, Laura Pardo, Paula Cruz Toro, Agnes Hernandez-Biette, Carlos Martinez-Rivera and Ignasi Garcia-Olive Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Thu Oct 2 08:19:47 2025 CEST ModDate: Thu Oct 2 08:22:23 2025 CEST Custom Metadata: yes Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 10 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 223028 bytes Optimized: no PDF version: 1.5 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- MIKRSI+VnURWPalladioL Type 1 Custom yes yes yes 76 0 PDTNFA+URWPalladioL-Roma Type 1 Custom yes yes yes 77 0 HXRLTY+URWPalladioL-Ital Type 1 Custom yes yes yes 78 0 IIXGGX+URWPalladioL-Bold Type 1 Custom yes yes yes 79 0 QLBIEB+URWPalladioL-BoldItal Type 1 Custom yes yes yes 147 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2026-04-22 04:05:39 CEST RepresentationInformation: 327777.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2026-04-21 10:50:52 CEST Size: 223028 Format: PDF Version: 1.5 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 253 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: true CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Item: Title: Methods Children: Item: Title: Setting Item: Title: Population Item: Title: Statistical Analysis Item: Title: Ethical Aspects Item: Title: Results Item: Title: Discussion Item: Title: References Info: Title: Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab Author: Carlota Gonzalez-Lluch, Maria Basagaña, Laura Pardo, Paula Cruz Toro, Agnes Hernandez-Biette, Carlos Martinez-Rivera and Ignasi Garcia-Olive Subject: Background: This study aimed to evaluate the clinical effectiveness of dupilumab and its impact on CRSwNP and type 2 inflammatory biomarkers in patients with severe uncontrolled asthma, with or without comorbidities, within a real-life cohort. Methods: This was a single-center, prospective, and observational real-life study conducted at the Severe Asthma Unit of Germans Trias i Pujol University Hospital. The objective of this study was to assess the real-world response to dupilumab treatment in patients with severe asthma, with or without nasal polyposis, bronchiectasis, obesity, or switching from another biologic drug for their asthma. Results: The ACT score significantly increased (13.7 vs. 20.6; p = 0.001), while the number of exacerbations decreased (3.1 vs. 0.7; p = 0.005). Patients with CRSwNP showed an increase in the ACT score (13.1 vs. 19.8; p = 0.011) and a decrease in the number of exacerbations (3.0 vs. 1.3; p = 0.217). Patients with nasal polyps showed an increase in both SNOT22 (78.3 vs. 38.3; p = 0.013) and global VAS (8 vs. 4.2; p = 0.028). Patients with bronchiectasis receiving dupilumab showed an increase in the ACT score (12.7 vs. 21.3; p = 0.039) and a marked decrease in the number of exacerbations (2.8 vs. 0; p = 0.025). Obese patients treated with dupilumab showed an improvement in the ACT score (14.1 vs. 21.3; p = 0.044) and a decrease in the rate of exacerbations (3.2 vs. 1.3; p = 0.030). Patients with rhinoconjunctivitis receiving dupilumab showed an increase in the ACT score (13.4 vs. 19.1; p = 0.017) and a decrease in the number of exacerbations (3.3 vs. 0.8; p = 0.024). Conclusions: Dupilumab is a highly effective treatment for severe asthma, showing significant improvements in lung function, reductions in exacerbations, and enhanced quality of life for patients with and without nasal polyps. The results of this real-life study support dupilumab as a valuable addition to the therapeutic armamentarium for asthma, particularly for those with type 2 inflammation despite the presence of comorbidities such as bronchiectasis or obesity, or for patients in whom a previous biologic treatment failed. Keywords: asthma; comorbidities; dupilumab; personalized medicine; real-life study Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Thu Oct 02 08:19:47 CEST 2025 ModDate: Thu Oct 02 08:22:23 CEST 2025 ID: 0xc8f8fcec428b7a9e50d9a35534e5ff16, 0xdc767617dc43e0da3aaf5595f2a269c2 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: QLBIEB+URWPalladioL-BoldItal FontSubset: true FirstChar: 110 LastChar: 112 FontDescriptor: FontName: QLBIEB+URWPalladioL-BoldItal Flags: Symbolic FontBBox: -170, -300, 1073, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: MIKRSI+VnURWPalladioL FontSubset: true FirstChar: 225 LastChar: 225 FontDescriptor: FontName: MIKRSI+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: PDTNFA+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 252 FontDescriptor: FontName: PDTNFA+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: HXRLTY+URWPalladioL-Ital FontSubset: true FirstChar: 45 LastChar: 121 FontDescriptor: FontName: HXRLTY+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: IIXGGX+URWPalladioL-Bold FontSubset: true FirstChar: 3 LastChar: 241 FontDescriptor: FontName: IIXGGX+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 77, 177, 152, 186 Annotation: Subtype: Link Rect: 34, 165, 103, 174 Annotation: Subtype: Link Rect: 36, 75, 152, 84 Annotation: Subtype: Link Rect: 34, 63, 89, 72 Annotation: Subtype: Link Rect: 34, 773, 176, 809 Annotation: Subtype: Link Rect: 515, 773, 560, 809 Annotation: Subtype: Link Rect: 161, 650, 172, 663 Annotation: Subtype: Link Rect: 422, 27, 560, 37 Annotation: Subtype: Link Rect: 34, 356, 87, 375 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 534, 714, 541, 723 ActionDest: 46 Annotation: Subtype: Link Rect: 343, 644, 350, 653 ActionDest: 46 Annotation: Subtype: Link Rect: 361, 449, 368, 458 ActionDest: 46 Annotation: Subtype: Link Rect: 369, 449, 376, 458 ActionDest: 46 Annotation: Subtype: Link Rect: 202, 393, 209, 402 ActionDest: 46 Annotation: Subtype: Link Rect: 266, 365, 273, 374 ActionDest: 46 Annotation: Subtype: Link Rect: 549, 338, 556, 347 ActionDest: 46 Annotation: Subtype: Link Rect: 429, 296, 436, 305 ActionDest: 46 Annotation: Subtype: Link Rect: 389, 282, 396, 291 ActionDest: 46 Annotation: Subtype: Link Rect: 389, 198, 396, 207 ActionDest: 46 Annotation: Subtype: Link Rect: 397, 198, 404, 207 ActionDest: 46 Page: Sequence: 3 Page: Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 433, 561, 440, 573 ActionDest: 96 Annotation: Subtype: Link Rect: 231, 450, 238, 462 ActionDest: 96 Annotation: Subtype: Link Rect: 258, 394, 265, 406 ActionDest: 96 Annotation: Subtype: Link Rect: 239, 310, 246, 322 ActionDest: 97 Annotation: Subtype: Link Rect: 520, 310, 527, 322 ActionDest: 97 Annotation: Subtype: Link Rect: 549, 283, 556, 295 ActionDest: 97 Annotation: Subtype: Link Rect: 460, 241, 467, 253 ActionDest: 97 Annotation: Subtype: Link Rect: 504, 241, 511, 253 ActionDest: 97 Annotation: Subtype: Link Rect: 466, 143, 473, 155 ActionDest: 41 Annotation: Subtype: Link Rect: 259, 115, 266, 127 ActionDest: 96 Page: Sequence: 5 Page: Sequence: 6 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 484, 473, 491, 482 ActionDest: 46 Annotation: Subtype: Link Rect: 334, 375, 341, 384 ActionDest: 46 Annotation: Subtype: Link Rect: 437, 375, 449, 384 ActionDest: 46 Annotation: Subtype: Link Rect: 192, 306, 199, 315 ActionDest: 46 Annotation: Subtype: Link Rect: 200, 306, 212, 315 ActionDest: 46 Annotation: Subtype: Link Rect: 212, 306, 224, 315 ActionDest: 46 Annotation: Subtype: Link Rect: 328, 152, 340, 162 ActionDest: 46 Annotation: Subtype: Link Rect: 417, 125, 429, 134 ActionDest: 46 Annotation: Subtype: Link Rect: 277, 111, 289, 120 ActionDest: 173 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 441, 744, 453, 754 ActionDest: 173 Annotation: Subtype: Link Rect: 453, 731, 465, 740 ActionDest: 173 Annotation: Subtype: Link Rect: 181, 717, 193, 726 ActionDest: 173 Annotation: Subtype: Link Rect: 438, 522, 450, 531 ActionDest: 173 Annotation: Subtype: Link Rect: 450, 522, 462, 531 ActionDest: 173 Annotation: Subtype: Link Rect: 426, 466, 438, 475 ActionDest: 173 Annotation: Subtype: Link Rect: 252, 438, 264, 447 ActionDest: 173 Annotation: Subtype: Link Rect: 383, 327, 395, 336 ActionDest: 173 Page: Sequence: 9 Annotations: Annotation: Subtype: Link Rect: 519, 574, 557, 585 Annotation: Subtype: Link Rect: 59, 562, 95, 572 Annotation: Subtype: Link Rect: 90, 524, 128, 534 Annotation: Subtype: Link Rect: 134, 524, 170, 534 Annotation: Subtype: Link Rect: 59, 485, 96, 495 Annotation: Subtype: Link Rect: 102, 485, 138, 495 Annotation: Subtype: Link Rect: 202, 434, 240, 444 Annotation: Subtype: Link Rect: 225, 395, 262, 406 Annotation: Subtype: Link Rect: 363, 357, 400, 368 Annotation: Subtype: Link Rect: 185, 319, 222, 329 Annotation: Subtype: Link Rect: 237, 293, 275, 304 Annotation: Subtype: Link Rect: 162, 255, 200, 266 Annotation: Subtype: Link Rect: 126, 217, 164, 227 Annotation: Subtype: Link Rect: 127, 179, 164, 189 Annotation: Subtype: Link Rect: 495, 152, 533, 163 Annotation: Subtype: Link Rect: 260, 114, 297, 125 Annotation: Subtype: Link Rect: 303, 114, 339, 125 Annotation: Subtype: Link Rect: 146, 76, 183, 87 Page: Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 82, 731, 119, 742 Annotation: Subtype: Link Rect: 125, 731, 161, 742 Annotation: Subtype: Link Rect: 185, 693, 222, 703 Annotation: Subtype: Link Rect: 141, 668, 178, 678 Annotation: Subtype: Link Rect: 435, 641, 473, 652 Annotation: Subtype: Link Rect: 224, 603, 261, 614 Annotation: Subtype: Link Rect: 364, 565, 402, 576 Annotation: Subtype: Link Rect: 174, 527, 211, 537 Annotation: Subtype: Link Rect: 59, 489, 96, 499 Annotation: Subtype: Link Rect: 102, 489, 138, 499 Annotation: Subtype: Link Rect: 395, 450, 433, 461 Checksum: 1708fed3 Type: CRC32 Checksum: 7fd400d1bdcf1839fee87498bceec5d5 Type: MD5 Checksum: 57473f45f17ebd901efedb48218248a07a7527e1 Type: SHA-1 Checksum: e81e67918b759ccee82096da6e6ff77aaf3c4b33b6f361378165cc50893928d1 Type: SHA-256